Rhythm Pharmaceuticals Inc’s recent filing unveils that its Corporate Controller & CAO German Christopher Paul unloaded Company’s shares for reported $0.14 million on Jun 10 ’25. In the deal valued at $67.19 per share,2,069 shares were sold. As a result of this transaction, German Christopher Paul now holds 1,889 shares worth roughly $0.12 million.
Then, Cramer Pamela J. sold 7,031 shares, generating $478,435 in total proceeds. Upon selling the shares at $68.05, the Chief Human Resources Officer now owns 19,209 shares.
Before that, CHRISTOPHER PAUL GERMAN bought 2,069 shares. Rhythm Pharmaceuticals Inc shares valued at $138,044 were divested by the Officer at a price of $66.72 per share.
BofA Securities upgraded its Rhythm Pharmaceuticals Inc [RYTM] rating to a Buy from a a Neutral in a research note published recently. Jefferies began covering RYTM with “Buy” recommendation on January 02, 2025. Oppenheimer started covering the stock on December 20, 2024. It rated RYTM as “an Outperform”.
Price Performance Review of RYTM
On Monday, Rhythm Pharmaceuticals Inc [NASDAQ:RYTM] saw its stock jump 0.73% to $63.19. Over the last five days, the stock has gained 1.71%. Rhythm Pharmaceuticals Inc shares have risen nearly 58.49% since the year began. Nevertheless, the stocks have risen 12.88% over the past one year. While a 52-week high of $69.89 was reached on 06/09/25, a 52-week low of $39.46 was recorded on 04/07/25.
Levels Of Support And Resistance For RYTM Stock
The 24-hour chart illustrates a support level at 62.32, which if violated will result in even more drops to 61.45. On the upside, there is a resistance level at 64.03. A further resistance level may holdings at 64.87.
How much short interest is there in Rhythm Pharmaceuticals Inc?
A steep rise in short interest was recorded in Rhythm Pharmaceuticals Inc stocks on 2025-06-13, dropping by -0.31 million shares to a total of 4.76 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 5.07 million shares. There was a decline of -6.59%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on October 21, 2024 when Guggenheim began covering the stock and recommended ‘”a Buy”‘ rating along with a $70 price target.
